Privately held biotech Xenome has begun a Phase II trial of lead candidate Xen2174 for the control of acute post-operative pain.

The trial will enrol approximately 200 patients at multiple clinical sites in the US.

The aim is to evaluate the safety and efficacy of Xen2174 administered as a single intrathecal administration to patients undergoing unilateral bunionectomy, a standard model for the assessment of acute pain therapies.

Xenome is also in Phase II trials of Xen2174 for chronic pain.